Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for povetacicept in IgA nephropathy following the Phase 3 readout. The successful povetacicept Phase 3 outcome in IgA nephropathy fits into a wider picture that recent research brings...